Results of a multivariate analysis for potential factors affecting outcome in translocation related sarcomas (TRS) treated with trabectedin or doxorubicin-based chemotherapy (DXCT) as first-line therapy

被引：0
|
作者：
Chawla, S. P. [1 ]
Leahy, M. G. [2 ]
Italiano, A. [3 ]
Patel, S. [4 ]
Penel, N. [5 ]
Piperno-Neumann, S. [6 ]
Lardelli, P. [7 ]
Soto-Matos, A. [7 ]
Nieto, A. [7 ]
Blay, J. Y. [8 ]
机构：
[1] Sarcoma Onc Ctr, Santa Monica, CA USA
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Inst Bergonie, Bordeaux, France
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Ctr Oscar Lambret, F-59020 Lille, France
[6] Inst Curie, Paris, France
[7] PharmaMar, Clin Oncol, Madrid, Spain
[8] Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3829
引用
收藏
页码：S885 / S885
页数：1
相关论文
共 18 条
  • [1] Safety of trabectedin versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients with translocation-related sarcoma (TRS)
    Chawla, S. P.
    Italiano, A.
    Patel, S.
    Hohenberger, P.
    Santoro, A.
    Staddon, A. P.
    Lardelli, P.
    Gomez, J.
    Kahatt, C.
    Blay, J. Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S885 - S885
  • [2] Results of the randomized phase III trial of trabectedin (F) versus doxorubicin-based chemotherapy (DXCT) as First-line therapy in patients (pts) with translocation-related sarcoma (TRS).
    Hendifar, Andrew Eugene
    Chawla, Sant P.
    Leahy, Michael Gordon
    Italiano, Antoine
    Patel, Shreyaskumar
    Santoro, Armando
    Staddon, Arthur P.
    Penel, Nicolas
    Piperno-Neumann, Sophie
    Demetri, George D.
    Hayward, Larry
    White, Jeff
    Gouw, Launce G.
    De Miguel, Bernardo
    Lardelli, Pilar
    Soto, Arturo
    Nieto, Antonio
    Blay, Jean-Yves
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
    Blay, Jean-Yves
    Leahy, Michael G.
    Binh Bui Nguyen
    Patel, Shreyaskumar R.
    Hohenberger, Peter
    Santoro, Armando
    Staddon, Arthur P.
    Penel, Nicolas
    Piperno-Neumann, Sophie
    Hendifar, Andrew
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Chawla, Sant P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (06) : 1137 - 1147
  • [4] Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).
    Blay, Jean-Yves
    Leahy, Michael Gordon
    Binh Bui Nguyen
    Patel, Shreyaskumar
    Santoro, Armando
    Hohenberger, Peter
    Demetri, George D.
    Lardelli, Pilar
    Perez, Iratxe
    Chawla, Sant P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] BRCA1 expression exploratory analysis in patients of the phase III trial of trabectedin vs. doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
    Aracil, M.
    Lardelli, P.
    Nieto, A.
    Galmarini, C. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 17 - 17
  • [6] Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy
    Zduniak, Alexandra
    Leveque, Emilie
    Perdrix, Anne
    Etancelin, Pascaline
    Menard, Anne-Lise
    Lenain, Pascal
    Contentin, Nathalie
    Pepin, Louis-Ferdinand
    Lepretre, Stephane
    Lemasle, Emilie
    Lanic, Helene
    Stamatoullas-Bastard, Aspasia
    Kammoun-Quique, Leila
    Tilly, Herve
    Bauer, Fabrice
    Jardin, Fabrice
    Camus, Vincent
    [J]. LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3340 - 3350
  • [7] Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies
    Sleijfer, S.
    Ouali, M.
    Van Glabbeke, M.
    Krarup-Hansen, A.
    Leahy, M. G.
    Rodenhuis, S.
    Le Cesne, A.
    Hogendoorn, P. C.
    Verweij, J.
    Blay, J. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Clinical and molecular factors predictive of outcome with first-line sorafenib-based therapy in advanced renal carcinoma (RCC): An analysis of SWOG 0412
    Goldman, B. H.
    Lara, P. N., Jr.
    Beer, T. M.
    Mack, P. C.
    Drabkin, H. A.
    Holland, W. S.
    Crawford, E.
    Ryan, C. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: A retrospective analysis of single institution
    Inal, A.
    Kaplan, M. A.
    Kucukoner, M.
    Karakus, A.
    Isikdogan, A.
    [J]. JOURNAL OF BUON, 2012, 17 (03): : 533 - 536
  • [10] Prognostic factors for overall survival in patients with advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: A post-hoc analysis of JCOG1213
    Hirano, Hidekazu
    Hirata, Kenro
    Honma, Yoshitaka
    Morizane, Chigusa
    Machida, Nozomu
    Kato, Ken
    Okusaka, Takuji
    Boku, Narikazu
    Sekine, Shigeki
    Hiraoka, Nobuyoshi
    Ogawa, Gakuto
    Sano, Yusuke
    Shibuya, Yuichi
    Takahashi, Masanobu
    Fujimori, Nao
    Nomura, Motoo
    Doki, Yuichiro
    Ueno, Makoto
    Yoshikawa, Takaki
    Takeuchi, Hiroya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 594 - 594
12